483
Colgin, IncFDA 483 - Colgin, Inc - September 21, 2023
Record Details
Colgin, Inc., a drug manufacturer in Dallas, TX, was cited for significant deficiencies in its quality control unit, manufacturing processes, and facility maintenance during an FDA inspection. The firm failed to follow written procedures, validate processes, test raw materials and finished products, and used expired ingredients, indicating a severe lack of cGMP adherence. The facility also showed poor sanitation and equipment maintenance.
Open in Dashboard
ID · a98d3544-1983-44af-ab64-aac4a33f8652